
HURA Stock Forecast & Price Target
HURA Analyst Ratings
Bulls say
TuHURA Biosciences is attractive because its lead IFx-2.0 program has already produced encouraging Phase 1b/2a data, with all three evaluable deep-seated MCC patients achieving durable partial responses and keytruda-based activity potentially de-risking the ongoing Phase 3 trial. The company also offers multiple near-term catalysts across MSDC inhibitors, TBS-2025, and anti-VISTA development, while FDA written responses and orphan-drug recognition support a credible regulatory path and broaden the long-term opportunity in MCC and AML. Financially, 3Q26 net loss was $0.10 per share versus expectations for $0.14, R&D and SG&A were only $3.7M and $2.0M, and ~$1.9M cash plus a $50M credit facility may fund operations into 2028.
Bears say
TuHURA Biosciences is a high-risk clinical-stage immuno-oncology company whose lead assets face substantial probability of failure because drug development often fails to show sufficient efficacy or safety in trials. Its ability to create value depends on FDA and other regulatory approvals, yet any delay or denial could materially impair commercialization and weigh on the share price. The outlook is further pressured by intense competition from better-capitalized biotech and pharmaceutical rivals, while anticipated additional equity financing to fund development raises dilution risk for existing shareholders.
This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
HURA Analyst Forecast & Price Prediction
Start investing in HURA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About TuHURA Biosciences Inc (HURA) Forecast
HURA Analyst Forecast & Price Prediction
Start investing in HURA
Order type
Buy in
Order amount
Est. shares
0 shares